Influence of biochemical parameters of liver function on vancomycin pharmacokinetics

Pharmacology and Toxicology

Volumn 79, Issue 2, 1996, Pages 55-59

  Marti R ^a   Rosell, M ^a   Pou, L ^a   Garcia L ^a   Pascual, C ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL;

EID: 0029816467     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1996.tb00242.x     Document Type: Article

References (24)

1. Albrecht, L. M., M. J. Rybak, S. C. Boike & S. Pancorbo: Comparison of serum sampling methods for determining vancomycin dosageregimens. Therap. Drug Monit. 1988, 10, 85-90.
2. Brown, J., P. Altmann, J. Cunningham, E. Shaw & F. Marsch: Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis. J. Antimicrob. Chemotherap. 1990, 25, 141-147.
3. Brown, N., D. H. W. Ho, K. L. Fong, L. Bogerd, A. Maksymiuk, R. Bolivar, V. Fainstein & G. P. Bodey: Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob. Agents Chemotherap. 1983, 23, 603-609.
4. Campos, F., L. Pou, A. López & L. Garcia. Vancomycin pharmacokinetics in hematologic cancer patients. In: Recent developments in therapeutic drug monitoring and clinical toxicology. Ed.: I. Sunshine. Marcel Dekker, Inc. Palo Alto, California, 1992, pp 215-219.
5. Chen, Y., R .L. G. Norris, J. J. Schneider & P. J. Ravenscroft: The influence of vancomycin concentration and the pH of plasma on vancomycin protein binding. J.P.M. 1992, 28, 57-60.
6. Cockroft, D. W. & M. H. Gault: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16, 31-41.
7. Cutler, N. R., P. L. Narag, L. J. Lesko, M. Ninos & M. Power: Vancomycin disposition: The importance of age. Clin. Pharmacol. Therap. 1984, 36, 803-810.
8. Ena, J., R. W. Dick, R. N. Jones & R. P. Wenzel: The epidemiology of intravenous vancomycin usage in a University Hospital. A 10 year study. J.A.M.A. 1993, 269, 598-602.
9. Fernández, de Gata, M. M., I. Fruns, J. M. Hernández, D. Caballero, J. F. San Miguel, J. Martinez Lanao & A. Domínguez-Gil: Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin. Pharm. 1993, 12, 515-520.
10. Garrelts, J. C., P. J. Godley, M. W. Horton & J. A. Karboski: Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Clin. Pharm. 1987, 6, 795-799.
11. Higa, G. M. & W. E. Murray: Alterations in aminoglycoside pharmacokinetics in patients with cancer. Clin. Pharm. 1987, 6, 963-966.
12. Kaojarern, S., S. Maoleekoonpairoy & V. Atichartakarn: Pharmacokinetics of amikacin in hematologic malignancies. Antimicrob. Agents Chemotherap. 1989, 33, 1406-1408.
13. Macias, W. L., B. A. Mueller & S. K. Scarim: Vancomycin pharmacokinetics in acute renal failure; Preservation of nonrenal clearance. Clin. Pharmacol. Therap. 1991, 50, 688-694.
14. Matzke, G. R.: Vancomycin. In: Applied pharmacokinetics. Principles of therapeutic drug monitoring. Eds: Evans W. E., Shetang J. J. & Jusko W. J. Applied Therapeutics, Inc. Washington, 1986, pp. 399-436.
15. Moellering, R. C., D. J. Krogstad & D. J. Greenblatt: Vancomycin therapy in patients with impaired renal function: A nomogram for dosage. Ann. Inter. Med. 1981, 94, 343-346.
16. Pachorek, R. E. & F. Wood: Vancomycin half-life in a patient with hepatic and renal dysfunction. Clin. Pharm. 1991, 10, 297-300.
17. Pryka, R. D., K. A. Rodvold, M. Garrison & J. C. Rotschafer: Individualizing vancomycin dosage regimen:one vs two-compartment bayesian models. Therap. Drug Monit. 1989, 11, 450-454.
18. Rodvold, K. A., H. Zokufa & J. C. Rotschafer: Routine monitoring of serum vancomycin concentrations: can waiting be justified ? (Commentary). Clin. Pharm. 1987, 6, 795-799.
19. Rotschafer, J. C., K. Crossley, D. E. Zaske, K. Mead, R. J. Swachuk & L. D. Solem: Pharmacokinetics of vancomycin: Observations in 28 patients and dosage recommendations. Antimicrob. Agents Chemotherap. 1982, 22, 391-394.
20. Sayers, J. F. B. & R. Shimasaki: Routine monitoring of serum vancomycin concentrations: The answer lies in the middle. Clin. Pharm. 1988, 7, 18.
21. Sun, H. E., E. G. Maderazo & A. R. Krusell: Serum protein-binding characteristics of vancomycin. Antimicrob. Agents Chemotherap. 1993, 37, 1132-1136.
22. Tan, C. C., H. S. Lee, T. Y. Ti & E. C. J. Lee: Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Therap. Drug Monit. 1990, 9, 711-715.
23. Vance-Bryan, K., D. R. P. Guay, S. S. Gilliland, K. A. Rodvold & J. C. Rotschafer: Effect of obesity on vancomycin pharmacokinetics parameters as determined by using a bayesian forecasting technique. Antimicrob. Agents Chemotherap. 1993, 37, 436-440.
24. 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. J. Burn Care Rehabilit. 1989, 10, 425-428.